anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized, prospective study which will include a total of 200 patients who are scheduled to undergo major elective surgery with an anticipated blood loss of ≥ 500 ml. The research participants will be randomly assigned to a control group (n=100) that will receive the standard of care for intraoperative management by the anesthesia. Minimal resuscitation standards include a mean arterial pressure \> 65 mm Hg, SpO2 \> 90% and evidence of end-organ perfusion (i.e. mentation prior to induction of anesthesia, urine output \> 20 ml/hr) and absence of tachycardia (HR \< 100/min). The protocol group (n=100) will, in addition, receive further resuscitation to achieve an increased oxygen delivery (DO2) to a targeted of 600 ml/min/m2. This approach is called goal-directed therapy. This target DO2 will be achieved via a treatment algorithm that includes intraoperative volume expansion and/or dobutamine infusion, guided by the LiDCO cardiovascular monitoring of stroke volume and cardiac output. All patients will also have non-invasive tissue O2 saturation (StO2) monitoring using the InSpectra probe on their hand. Patients in the protocol group will be subdivided to 2 subgroups. Group one subjects will be those patients that are directly admitted to the ICU following surgery and group two subjects will be those patients discharged to the PAR and then a regular hospital ward. All subjects will continue to receive goal directed therapy for as long as they are in the PAR or ICU or until 8 hours of post-operative time has elapsed. All participants will be followed daily during their hospital stay to assess the development of complications, length of stay and discharge status. All patients will receive phone interview at one and 3 months after the surgery to inquire about their quality of life since their surgery using the SF36 instrument. The total duration of participant's commitment to the study will be 3 months, during which their lab and clinical data will be recorded. Statistical analysis of the data will be performed at the conclusion of the study period by professional statistician to determine the difference in the outcome and morbidity and mortality between the two groups using multiple logistic regression and Cox proportional hazard scoring with primary outcome variables being length of stay, total complications, and mortality.
OBJECTIVES: We present the original technique of compression hemostatic sutures on the lower uterine segment due to early postpartum hemorrhage during cesarean section, with a literature review.
METHODS: A retrospective clinical case study was conducted at the tertiary perinatal center. Twelve patients had nine planned and three urgent cesarean sections due to antenatally verified placenta previa and/or placenta accreta spectrum and defined early postpartum hemorrhage > 1000 mL during cesarean section. As the use of uterotonics failed to produce any effect and hemorrhage persisted, compression sutures of the lower uterine segment were made by our own technique, as follows: below the hysterotomy, a horizontal corrugated suture is placed from the right to the left corner and after 2-3 cm vertically and backwards at several sites from the left to the right corner, where it is tightened.
RESULTS: Seven patients had one cesarean section, three patients had two cesarean sections, and seven patients had pregnancy from the in vitro fertilization procedure in their history. There were six patients with placenta previa and six patients with anterior invasive placenta accreta or increta. Original hemostatic procedure was applied successfully in ten cases, and after placement of O'Leary suture and persistent bleeding in two cases. In this group, no hysterectomy was performed, and patients received blood transfusion of 440-880 mL. Three patients later had spontaneous pregnancies.
CONCLUSION: Our own hemostatic method with a simple technique, fast learning, and minimal logistics contributes to successful management of this currently global problem of morbidly adherent placenta previa.
BACKGROUND: Initiation of feeding after percutaneous endoscopic gastrostomy (PEG) placement has been debated. Randomized controlled trials (RCTs) have been performed on early feeding compared with delayed feeding after PEG placement with varying results. Therefore, a meta-analysis was conducted examining early vs delayed feeding after placement of a PEG.
METHODS: A comprehensive search of databases was conducted in January 2024. Peer-reviewed published RCTs comparing early feeding (≤4 h) with delayed feeding (>4 h) were identified and included in the meta-analysis. Meta-analysis was completed using pooled estimates of overall complications, individual complications, mortality ≤72 h, and number of day 1 significant gastric residual volumes.
RESULTS: Six RCTs (n = 467) were included in the analysis. Comparison of early feeding with delayed feeding after PEG showed no statistically significant differences for overall complications (P = 0.18), mortality ≤72 h (P = 0.3), and number of day 1 significant gastric residual volumes (P = 0.05). No differences were also noted for individual complications, including vomiting, wound infection, bleeding, or diarrhea.
CONCLUSION: Feeding ≤4 h after PEG have no differences in minor and major complications compared with that of delayed feeding. Early feeding ≤4 h is safe and should be recommended in future guidelines.
The invention relates to a CTL epitope polypeptide of cryptosporidium parvum, and the amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. Also provides nucleic acid for coding the CTL epitope polypeptide of the cryptosporidium parvum, and the nucleotide sequence of the nucleic acid is shown as SEQ ID NO. 2. The CTL epitope polypeptide P1 of the cryptosporidium parvum has good affinity with H-2Kb molecules or HLA-A0201 molecules respectively, and the CTL epitope polypeptide P1 has corresponding immunological functions. Provides a new direction for preparing the cryptosporidium parvum vaccine, and the polypeptide shows excellent stimulation response in polypeptide specificity CTL immune response in C57BL/6N mouse spleen cells, and has huge development and application potential in the field of cryptosporidium parvum specificity immunotherapy.
A medical image diagnostic apparatus which processes a medical image of a subject is shown. The apparatus includes the following. A power supply supplies power to each unit of the medical image diagnostic apparatus. A power supply button receives operation to end or start the medical image diagnostic apparatus. A power supply controller stands by to receive input of the power supply button and supplies power to the power supply and controls the power supply. A battery is mounted in the medical image diagnostic apparatus and supplies power to the power supply controller. A switch receives operation to switch between on and off, and electrically connects or cuts a path between the battery and the power supply controller in response to the operation.
Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity.
Of the 534 adult patients treated with CUBICIN in Phase 3 controlled clinical trials of complicated skin and skin structure infections (cSSSI), 27% were 65 years of age or older and 12% were 75 years of age or older. Of the 120 adult patients treated with CUBICIN in the Phase 3 controlled clinical trial of S. aureus bacteremia/endocarditis, 25% were 65 years of age or older and 16% were 75 years of age or older. In Phase 3 adult clinical trials of cSSSI and S. aureus bacteremia/endocarditis, clinical success rates were lower in patients ≥65 years of age than in patients <65 years of age. In addition, treatment-emergent adverse events were more common in patients ≥65 years of age than in patients <65 years of age.

The exposure of daptomycin was higher in healthy elderly subjects than in healthy young adult subjects. However, no adjustment of CUBICIN RF dosage is warranted for elderly patients with creatinine clearance (CLCR) ≥30 mL/min [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].
Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
OROS-MPH's pharmacokinetic profile uses an increasing delivery of MPH over the day (ascending pharmacokinetic curve). It was designed to replace IR-MPH TID treatment. Another new long-acting formulation is Metadate CD. Metadate CD consists of capsules with two types of beads. It was designed to replace IR-MPH BID treatment. The main target of MPH in the brain is the dopamine transporter (DAT). We have an exquisitely sensitive methodology to measure DAT occupancy using C-11 Altropane and Positron Emission Tomography (PET). The time course of decay of the C-11 Altropane permits repeated imaging, thus allowing documentation of the pharmacokinetics of DAT receptor occupancy.
The invention discloses an osteogenic growth peptide-calcitonin gene related peptide fusion protein and an encoding gene thereof and relates to the fusion protein and the encoding gene. The invention aims at providing the osteogenic growth peptide-calcitonin gene related peptide fusion protein and the encoding gene thereof and further getting the fusion protein which simultaneously has the double effects of treating osteoporosis and myocardial ischemia, wherein the two proteins can form complementary action and synergy. The amino acid sequence of the fusion protein is as shown in SEQ ID NO: 2. The nucleotide sequence of the encoding gene is as shown in SEQ ID NO: 1. The osteogenic growth peptide-calcitonin gene related peptide fusion protein disclosed by the invention can fuse an osteogenic growth peptide and a calcitonin gene related peptide, and enable the two, namely the osteogenic growth peptide and the calcitonin gene related peptide to form the complementary action and the synergy; and experiments prove that the fusion protein has great effects of treating the osteoporosis and the myocardial ischemia. The fusion protein disclosed by the invention can be used for preparing medicaments for preventing and treating the osteoporosis and the myocardial ischemia.
Disclosed are thrombin peptide derivatives comprising a polypeptide having the amino acid sequence SEQ ID NO. 2: Arg-Gly-Asp-Ala-Xaa-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val, or a C-terminal truncated fragment of the polypeptide having at least six amino acids. Xaa is alanine, glycine, serine, or an S-protected cysteine. Zero, one, two, or three amino acids in the polypeptide or polypeptide fragment differ from the corresponding position of SEQ ID NO. 2. Also disclosed are methods of treating a subject in need of treatment with a thrombin receptor agonist. The methods comprise the step of administering an effective amount of the thrombin peptide derivative described above.
Background. Intracardiac echocardiography (ICE) is routinely used in cardiac electrophysiology and catheterization labs. It plays a vital role in understanding cardiac anatomy, procedural planning, and early identification of complications. In this review, we describe the utility of ICE for procedures in the electrophysiology lab, including atrial fibrillation ablation, left atrial appendage occlusion device implantation, and cardiac implantable electronic device (CIED) extraction. Intracardiac echocardiography also helps in the identification of complications such as pericardial effusion, pulmonary vein stenosis, and left atrial appendage thrombus. Compared with traditional echocardiographic modalities such as transesophageal echocardiogram (TEE), ICE has equivalent image quality, requires less sedation, and possesses no risk of esophageal injury. The disadvantages of ICE include a learning curve and necessity for central vascular access.
A patient support apparatus for supporting a patient communicates wirelessly with one or more devices and determines the relative position of the device(s) with respect to the patient support apparatus. A control system onboard the patient support apparatus receives identification data from the device(s) and uses the identification data to perform an authentication analysis of the device. Based on the authentication analysis, the control system determines an authorization level for the device and transmits different types of data to the device based on the authorization level. A plurality of locator nodes may be included on the patient support apparatus that are linked together by an embedded network. Synchronization messages are passed between the locator nodes over the embedded network to ensure the locator nodes have synchronized time. The authentication analysis and/or the use of encrypted communications may be based on the identity of the device and/or its location.
Depression is a debilitating mood disorder that causes persistent feelings of sadness, emptiness, and a loss of joy. However, the clinical efficacy of representative drugs for depression, such as selective serotonin reuptake inhibitors, remains controversial. Therefore, there is an urgent need for more effective therapies to treat depression. Neuroinflammation and the hypothalamic-pituitary-adrenal (HPA) axis are pivotal factors in depression. Inulae Flos (IF), the flower of Inula japonica Thunb, is known for its antioxidant and anti-inflammatory effects. This study explored whether IF alleviates depression in both in vitro and in vivo models. For in vitro studies, we treated BV2 and PC12 cells damaged by lipopolysaccharides or corticosterone (CORT) with IF to investigate the mechanisms of depression. For in vivo studies, C57BL/6 mice were exposed to chronic restraint stress and were administered IF at doses of 0, 100, and 300 mg/kg for 2 weeks. IF inhibited pro-inflammatory mediators, such as nitric oxide, inducible nitric oxide synthase, and interleukins in BV2 cells. Moreover, IF increased the viability of CORT-damaged PC12 cells by modulating protein kinase B, a mammalian target of the rapamycin pathway. Behavioral assessments demonstrated that IF reduced depression-like behaviors in mice. We found that IF reduced the activation of microglia and astrocytes, and regulated synapse plasticity in the mice brains. Furthermore, IF lowered elevated CORT levels in the plasma and restored glucocorticoid receptor expression in the hypothalamus. Collectively, these findings suggest that IF can alleviate depression by mitigating neuroinflammation and recovering dysfunction of the HPA-axis.
Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count \> 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
Participants will receive placebo TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
The invention relates to an application of an extract of Chimonanthus Salicifolius. S.Y.H. in preparation of a gastric cancer treating medicine. The application of Chimonanthus Salicifolius. S.Y.H. oil in preparation of gastric cancer treating medicine is characterized in that the extract of Chimonanthus Salicifolius. S.Y.H. is used for preparing a medicine for inhibiting proliferation of gastric cancer SGC-7901 cells and inducing cell apoptosis. Due to the fact that the Chimonanthus Salicifolius. S.Y.H. is a plant widely growing in the South, with the adoption of the extract as a digestive tract tumor medicine, the material is not only easy to obtain, but also can be effectively used as the gastric cancer treating medicine, the treating cost is reduced, the treatment plan is simplified and the medicine is safe and reliable.
AIMS: The genetic causes of epilepsy with unknown etiology in most patients remain unknown. The aim of this study was to elucidate the phenotype of SCAF4-related epilepsy.
METHODS: Trio-based whole-exome sequencing was performed in patients with epilepsy. Silico programs and protein modeling were employed to predict the damaging of variants. Previously reported SCAF4 variants were systematically reviewed to analyze the genotype-phenotype correlations.
RESULTS: Three heterozygous variants in the SCAF4 were detected in three cases, including one missense variant and two frameshift variants. All variants were de novo. None of these variants is present in gnomAD controls. The missense variant was predicted to be damaging in silico tools. Protein modeling showed that two frameshift variants resulted in loss of domains, and the missense variant may disrupt a nearby phosphorylation site and alter the hydrogen bonds around 54C and the stability of the SCAF4 protein. Intellectual development was mildly delayed for all patients except for one with whom contact was lost. All probands experienced epilepsy as infrequent seizures, responded well to antiseizure drugs, and had a median [IQR] seizure onset age of 4 [1.75, 7.5] years. The variants in the domain-encoding exons and upstream exons exhibited a strong association with epilepsy.
CONCLUSIONS: SCAF4 is a potential causative gene of epilepsy with neurodevelopmental disorders.
Cardiovascular (CV) diseases including heart failure are the leading causes of morbidity, with age being the primary risk factor. The combination of age-related organic functional impairment and reduced physical fitness can drastically impact an individual's healthspan. One's lifespan can potentially be prolonged by the preservation or improvement of physical fitness. However, it remains unclear as to which biomarkers are most suitable for distinguishing between healthy aging and the impaired organ function associated with heart failure. Therefore, a comprehensive assessment of the components of physical fitness and CV function will be performed to identify the most important factors contributing to aging in relation to both health and disease.

This cross-sectional investigation will consist of two parts: the COmPLETE-Health (C-Health) and COmPLETE-Heart (C-Heart) studies. C-Health will examine the aging trajectories of physical fitness components and CV properties in a healthy population sample aged between 20 and 100 years (n = 490). Separately, C-Heart will assess the same markers in patients at different stages of chronic heart failure (n = 80). The primary outcome to determine the difference between C-Health and C-Heart will be cardiorespiratory fitness as measured by cardiopulmonary exercise testing on a bicycle ergometer. Secondary outcomes will include walking speed, balance, isometric strength, peak power, and handgrip strength. Physical activity as a behavioural component will be assessed objectively via accelerometry. Further, CV assessments will include pulse wave velocity; retinal, arterial, and venous diameters; brachial and retinal arterial endothelial function; carotid intima-media thickness; and systolic and diastolic function. The health distances for C-Health and C-Heart will be calculated using the methodology based on statistical (Mahalanobis) distance applied to measurements of quantitative biomarkers.

This research seeks to identify physical fitness and CV biomarkers that best resemble underlying CV risk with age. Further, it will examine which physical fitness markers are impaired most in heart failure. The presented integrative approach could define new recommendations for diagnostic guidance in aging. Ultimately, this study is expected to offer a better understanding of which functional characteristics should be specifically targeted in primary and secondary prevention to achieve an optimal healthspan.
Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
Large-pore mesoporous silica nanoparticles (MSN) were prepared and functionalized to serve as a robust and biocompatible delivery platform for platinum-acridine (PA) anticancer agents. The material showed a high loading capacity for the dicationic, hydrophilic hybrid agent [PtCl(en)(N-[acridin-9-ylaminoethyl]-N-methylropionamidine)] dinitrate salt (P1 Al) and virtually complete retention of payload at neutral pH in a high-chloride buffer. In acidic media mimicking the pH inside the cells' lysosomes, rapid, burst-like release of P1 A1 from the nanoparticles is observed. Coating of the materials in phospholipid bilayers resulted in nanoparticles with greatly improved colloidal stability. The lipid and carboxylate- modified nanoparticles containing 40 wt. % drug caused S phase arrest and inhibited cell proliferation in pancreatic cancer cells at submicromolar concentrations similar to carrier-free P1A1. One feature of the nanoparticle-delivered P1A1 was that the payload did not escape from the acidified lysosomal vesicles into the cytoplasm, but was shuttled to the nuclear membrane and released into the nucleus.
FIELD: medicine.SUBSTANCE: group of inventions refers to nuclear medicine. Kit for preparing a suspension of polypeptide biodegradable microparticles for conducting transarental radioembolisation of liver capillaries contained in isotonic 0.9 % aqueous solution of sodium chloride labelled with a rhenium isotope consisting of auxiliary reagents: antioxidant - ascorbic acid in amount of 10 mg; rhenium reducing agent to a lower valence state - tin dihydrate chloride - 13.3 mg; emulsifier - polysorbate-80 - 2.5 mg; polypeptide radionuclide carrier - human blood albumen microsphere with diameter of 20–40 mcm - 10 mg; transhecalator and stabilizer pH-K, Na- tartaric acid (tartrate K, Na) - 18.9 mg; wherein all auxiliary reagents are packaged in three bottles: in bottle No. 1 contains a mixture of a reducing agent and an antioxidant, in bottle No. 2 there is a mixture of a polypeptide carrier of radionuclide and emulsifier atoms, flask No. 3 contains a transhecalator and a pH stabilizer which enables to achieve the pH value of the polypeptide biodetibular microparticles suspension in isotonic 0.9 % aqueous solution of sodium chloride, labelled with rhenium isotope in range from 2 to 5, wherein content of each flask is sterile and lyophilised. Also disclosed is a sequential three-stage method of producing a polypeptide biodetibular microparticle suspension.EFFECT: group of inventions provides therapy of malignant growths in liver.4 cl, 1 dwg, 1 tbl
NEW MATERIAL:A compound shown by formula I [R<1> is H, lower alkyl, halogen, etc.; R<2> is H, lower alkyl, etc.; X is -O- or -S-; Y is single bond, lower alkylene, etc.; Z is lower alkylene, etc.] and a salt thereof. EXAMPLE:N-(2-Nitroxyethyl)-4-thiazolecarboxamide. USE:A vasodilator having vasodilating action on blood vessel and long durability. PREPARATION:According to the reaction formula, a compound shown by formula II or a reactive derivative at the carboxyl group thereof or a salt thereof is reacted with a compound shown by formula II or a reactive derivative at the amino group thereof or a salt thereof to give a compound shown by formula I or a salt thereof.